The Brady Lab seeks to uncover how changes to chromatin states can drive the progression to NEPC and identify novel transcriptional regulators that cooperate with epigenetic changes to promote lineage plasticity. To address these goals, we utilize several different in vitro and in vivo models, including human prostate cancer cell lines, CRPC and NEPC patient-derived organoids, and transgenic mice. By applying next-generation sequencing approaches with single-cell resolution to these different models, we aim to shed light on the mechanistic underpinnings of treatment resistance and the molecular sequence of events underlying progression to NEPC. The Brady Lab is based in New York City at the Department of Pathology and Laboratory Medicine of Weill Cornell Medicine.
Research is to see what everybody else has seen, and to think what nobody else has thought.
- Albert Szent-Györgyi
The Lab Team
The Brady lab welcomes a diverse set of talents and fosters an interdisciplinary approach in its attempts to understand the biological mechanisms behind neuroendocrine prostate cancer.
Our Research
The Brady Lab seeks to uncover how changes to chromatin states can drive the progression to NEPC and identify novel transcriptional regulators that cooperate with epigenetic changes to promote lineage plasticity.